161 related articles for article (PubMed ID: 29479845)
1. Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis.
Chouaid C; Assié JB; Andujar P; Blein C; Tournier C; Vainchtock A; Scherpereel A; Monnet I; Pairon JC
Cancer Med; 2018 Apr; 7(4):1102-1109. PubMed ID: 29479845
[TBL] [Abstract][Full Text] [Related]
2. Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales.
Beckett P; Edwards J; Fennell D; Hubbard R; Woolhouse I; Peake MD
Lung Cancer; 2015 Jun; 88(3):344-8. PubMed ID: 25863904
[TBL] [Abstract][Full Text] [Related]
3. Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma.
Infante M; Morenghi E; Bottoni E; Zucali P; Rahal D; Morlacchi A; Ascolese AM; De Rose F; Navarria P; Crepaldi A; Testori A; Voulaz E; Errico V; Perrino M; Scorsetti M; Chiti A; Santoro A; Alloisio M
Eur J Cardiothorac Surg; 2016 Dec; 50(6):1077-1082. PubMed ID: 27330149
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
5. Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients.
Taioli E; Wolf AS; Camacho-Rivera M; Kaufman A; Lee DS; Nicastri D; Rosenzweig K; Flores RM
PLoS One; 2015; 10(12):e0145039. PubMed ID: 26660351
[TBL] [Abstract][Full Text] [Related]
6. Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982-2009.
Soeberg MJ; Leigh J; Driscoll T; Armstrong B; Young JM; van Zandwijk N
Occup Environ Med; 2016 Mar; 73(3):187-94. PubMed ID: 26800709
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP).
Rojas L; Cardona AF; Trejo-Rosales R; Zatarain-Barrón ZL; Ramírez-Tirado LA; Ruiz-Patiño A; Campos Gómez S; Corrales L; Oblitas G; Bacon L; Martín C; de Lima VCC; Freitas HC; Mas L; Vargas C; Carranza H; Otero J; Pérez MA; González L; Chirinos L; Granados ST; Rodriguez J; Báez R; Remolina Bonilla YA; Núñez Cerrillo G; Archila P; Cuello M; Karachaliou N; Rosell R; Arrieta O;
Thorac Cancer; 2019 Mar; 10(3):508-518. PubMed ID: 30706690
[TBL] [Abstract][Full Text] [Related]
8. Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study.
de Boer NL; van Kooten JP; Damhuis RAM; Aerts JGJV; Verhoef C; Madsen EVE
Ann Surg Oncol; 2019 Dec; 26(13):4222-4228. PubMed ID: 31620941
[TBL] [Abstract][Full Text] [Related]
9. Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database.
Zhuo M; Zheng Q; Chi Y; Jia B; Zhao J; Wu M; An T; Wang Y; Li J; Zhao X; Yang X; Zhong J; Chen H; Dong Z; Wang J; Zhai X; Wang Z
Thorac Cancer; 2019 May; 10(5):1193-1202. PubMed ID: 30951250
[TBL] [Abstract][Full Text] [Related]
10. Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study).
Raynaud C; Greillier L; Mazieres J; Monnet I; Mastroianni B; Robinet G; Fraboulet G; Dixmier A; Berard H; Lamy R; Letreut J; Lena H; Oliviero G; Botta S; Vergnenegre A; Borget I; Chouaid C
BMC Cancer; 2015 Nov; 15():857. PubMed ID: 26546402
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.
Wu TH; Lee LJ; Yuan CT; Chen TW; Yang JC
J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):230-236. PubMed ID: 29709339
[TBL] [Abstract][Full Text] [Related]
12. Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma.
Nelson DB; Rice DC; Niu J; Atay SM; Vaporciyan AA; Antonoff MB; Hofstetter WL; Walsh GL; Swisher SG; Roth JA; Tsao AS; Gomez DR; Giordano SH; Mehran RJ; Sepesi B
Eur J Cardiothorac Surg; 2018 May; 53(5):960-966. PubMed ID: 29211849
[TBL] [Abstract][Full Text] [Related]
13. Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma.
Batirel HF; Metintas M; Caglar HB; Ak G; Yumuk PF; Ahiskali R; Bozkurtlar E; Bekiroglu N; Lacin T; Yildizeli B; Yuksel M
J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2724-2733. PubMed ID: 29510939
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey.
Ceresoli GL; Grosso F; Zucali PA; Mencoboni M; Pasello G; Ripa C; Degiovanni D; Simonelli M; Bruzzone A; Dipietrantonj C; Piccolini E; Beretta GD; Favaretto AG; Giordano L; Santoro A; Botta M
Br J Cancer; 2014 Jul; 111(2):220-6. PubMed ID: 24918816
[TBL] [Abstract][Full Text] [Related]
15. Malignant pleural mesothelioma in Finland: regional and gender variation.
Laaksonen S; Ilonen I; Kuosma E; Sutinen E; Wolff H; Vehmas T; Husgafvel-Pursiainen K; Salo JA; Koli K; Räsänen J; Myllärniemi M
Acta Oncol; 2019 Jan; 58(1):38-44. PubMed ID: 30375909
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England.
Damhuis RA; Khakwani A; De Schutter H; Rich AL; Burgers JA; van Meerbeeck JP
Lung Cancer; 2015 Aug; 89(2):212-7. PubMed ID: 26044908
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database.
Van Gerwen M; Alpert N; Wolf A; Ohri N; Lewis E; Rosenzweig KE; Flores R; Taioli E
Carcinogenesis; 2019 Jun; 40(4):529-536. PubMed ID: 30649229
[TBL] [Abstract][Full Text] [Related]
19. Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes.
Linton A; Soeberg M; Broome R; Kao S; van Zandwijk N
Respirology; 2017 Jul; 22(5):978-985. PubMed ID: 28139858
[TBL] [Abstract][Full Text] [Related]
20. Disparities in Survival Due to Social Determinants of Health and Access to Treatment in US Patients With Operable Malignant Pleural Mesothelioma.
Alnajar A; Kareff SA; Razi SS; Rao JS; De Lima Lopes G; Nguyen DM; Villamizar N; Rodriguez E
JAMA Netw Open; 2023 Mar; 6(3):e234261. PubMed ID: 36951862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
